Evaluation of a 6-Month-Old Infant with Bronchiolitis and Disproportionate Tachycardia
A heart rate >200/min in a 6-month-old infant with bronchiolitis and minimal respiratory distress warrants immediate cardiac evaluation to rule out supraventricular tachycardia or other cardiac pathology, as this is not typical for uncomplicated bronchiolitis. 1, 2
Initial Assessment
Vital Sign Evaluation
- Confirm heart rate measurement over a full minute to ensure accuracy
- Compare with normal parameters for age (normal heart rate for 6-month-old: 80-160 bpm)
- Assess other vital signs:
- Respiratory rate (tachypnea defined as ≥70 breaths/minute may indicate severe disease)
- Oxygen saturation (obtain continuous pulse oximetry)
- Blood pressure
- Temperature (fever >38°C is associated with increased risk of major medical interventions) 3
Cardiac Assessment
- Obtain 12-lead ECG immediately to differentiate between:
- Sinus tachycardia (P waves present, normal PR interval)
- Supraventricular tachycardia (absent/abnormal P waves, narrow QRS)
- Other arrhythmias
- Auscultate for murmurs, gallops, or other abnormal heart sounds
- Assess perfusion: capillary refill, peripheral pulses, extremity temperature
Respiratory Assessment
- Evaluate work of breathing (retractions, nasal flaring, grunting)
- Auscultate for wheezing, crackles, or diminished breath sounds
- Note that the minimal respiratory distress with extreme tachycardia is discordant and suggests primary cardiac pathology
Differential Diagnosis
Primary cardiac pathology:
- Supraventricular tachycardia
- Myocarditis (may be triggered by the same virus causing bronchiolitis)
- Congenital heart disease with decompensation
- Cardiomyopathy
Bronchiolitis with complications:
- Dehydration causing compensatory tachycardia
- Hypoxemia (may be intermittent or not detected on spot checks)
- Fever/inflammation response
Other considerations:
- Sepsis
- Metabolic derangements (hypoglycemia, electrolyte abnormalities)
- Toxin exposure
Diagnostic Evaluation
First-line Tests
- ECG (immediate)
- Continuous pulse oximetry
- Point-of-care glucose measurement
Second-line Tests (based on initial findings)
- Echocardiogram if cardiac pathology suspected
- Electrolytes, BUN/creatinine if dehydration suspected
- CBC if infection/sepsis suspected
- Chest radiograph if cardiac enlargement or pneumonia suspected (not routine for bronchiolitis) 1
- Viral testing only if results would change management 1, 2
Management Algorithm
If SVT confirmed:
- Initiate SVT management protocol (vagal maneuvers, adenosine if needed)
- Cardiology consultation
- Admission for monitoring
If sinus tachycardia with minimal respiratory distress:
- Assess for dehydration (dry mucous membranes, decreased urine output, weight loss)
- Check for fever and treat if present
- Consider IV fluid bolus if signs of dehydration
- Evaluate for sepsis (blood culture, antibiotics if indicated)
If respiratory cause suspected:
Monitoring and Disposition
- Continuous cardiorespiratory and oxygen saturation monitoring
- Admission is indicated given the abnormal vital signs and need for close observation
- Consider PICU consultation if:
- Heart rate remains >200/min despite initial interventions
- Signs of hemodynamic instability develop
- Respiratory status deteriorates
- Diagnosis of SVT is confirmed
Important Caveats
- Normal respiratory rate does not exclude significant lower respiratory tract infection 1
- Infants under 6 months with bronchiolitis are at highest risk for major medical interventions within the first 5 days of illness 3
- Heart rate >200/min is above the expected range even for significant bronchiolitis and warrants cardiac evaluation
- Avoid routine use of bronchodilators, corticosteroids, or antibiotics unless specific indications exist 2, 5
- Hemodynamically significant congenital heart disease is a risk factor for severe bronchiolitis 1
Follow-up
- If cardiac pathology is identified, arrange appropriate cardiology follow-up
- If bronchiolitis is the primary diagnosis, educate caregivers about warning signs requiring return evaluation
- Consider RSV prophylaxis (palivizumab) if the infant has risk factors for severe disease 2